168 related articles for article (PubMed ID: 28087388)
1. Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis.
Saavedra-García P; Nichols K; Mahmud Z; Fan LY; Lam EW
Mol Cell Endocrinol; 2018 Feb; 462(Pt B):82-92. PubMed ID: 28087388
[TBL] [Abstract][Full Text] [Related]
2. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance.
Yao S; Fan LY; Lam EW
Semin Cancer Biol; 2018 Jun; 50():77-89. PubMed ID: 29180117
[TBL] [Abstract][Full Text] [Related]
3. Integrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
Li H; Tang X; Sun Z; Qu Z; Zou X
Biomol Biomed; 2024 May; 24(3):560-574. PubMed ID: 37976368
[TBL] [Abstract][Full Text] [Related]
4. Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance.
Gomes AR; Zhao F; Lam EW
Chin J Cancer; 2013 Jul; 32(7):365-70. PubMed ID: 23706767
[TBL] [Abstract][Full Text] [Related]
5. Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.
Ghosh S; Singh R; Vanwinkle ZM; Guo H; Vemula PK; Goel A; Haribabu B; Jala VR
Theranostics; 2022; 12(12):5574-5595. PubMed ID: 35910798
[TBL] [Abstract][Full Text] [Related]
6. Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance.
Zhao F; Lam EW
Front Med; 2012 Dec; 6(4):376-80. PubMed ID: 23124885
[TBL] [Abstract][Full Text] [Related]
7. Expression of FOXM1 and related proteins in breast cancer molecular subtypes.
Lee JJ; Lee HJ; Son BH; Kim SB; Ahn JH; Ahn SD; Cho EY; Gong G
Int J Exp Pathol; 2016 Apr; 97(2):170-7. PubMed ID: 27277416
[TBL] [Abstract][Full Text] [Related]
8. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression.
Gao Z; Li Z; Liu Y; Liu Z
Mol Genet Genomic Med; 2019 Mar; 7(3):e554. PubMed ID: 30623608
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the master regulator FOXM1 in cancer.
Liao GB; Li XZ; Zeng S; Liu C; Yang SM; Yang L; Hu CJ; Bai JY
Cell Commun Signal; 2018 Sep; 16(1):57. PubMed ID: 30208972
[TBL] [Abstract][Full Text] [Related]
11. STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment.
Silva LS; Goncalves LG; Silva F; Domingues G; Maximo V; Ferreira J; Lam EW; Dias S; Felix A; Serpa J
Tumour Biol; 2016 Apr; 37(4):5385-95. PubMed ID: 26563366
[TBL] [Abstract][Full Text] [Related]
12. Forkhead box M1 (FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer.
Abdeljaoued S; Bettaieb L; Nasri M; Adouni O; Goucha A; Bouzaiene H; Boussen H; Rahal K; Gamoudi A
Breast Dis; 2018; 37(3):109-114. PubMed ID: 29504520
[TBL] [Abstract][Full Text] [Related]
13. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
[TBL] [Abstract][Full Text] [Related]
14. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy.
Wierstra I
Adv Cancer Res; 2013; 119():191-419. PubMed ID: 23870513
[TBL] [Abstract][Full Text] [Related]
15. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells.
Yan D; Yan X; Dai X; Chen L; Sun L; Li T; He F; Lian J; Cai W
Oncol Rep; 2019 Aug; 42(2):785-796. PubMed ID: 31233189
[TBL] [Abstract][Full Text] [Related]
16. Forkhead Box Transcription Factors: Double-Edged Swords in Cancer.
Castaneda M; Hollander PD; Mani SA
Cancer Res; 2022 Jun; 82(11):2057-2065. PubMed ID: 35315926
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression.
Varghese V; Magnani L; Harada-Shoji N; Mauri F; Szydlo RM; Yao S; Lam EW; Kenny LM
Sci Rep; 2019 Feb; 9(1):1505. PubMed ID: 30728402
[TBL] [Abstract][Full Text] [Related]
18. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
19. Propofol disrupts cell carcinogenesis and aerobic glycolysis by regulating circTADA2A/miR-455-3p/FOXM1 axis in lung cancer.
Zhao H; Wei H; He J; Wang D; Li W; Wang Y; Ai Y; Yang J
Cell Cycle; 2020 Oct; 19(19):2538-2552. PubMed ID: 32857667
[TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
